Does Tigecycline Raise Liver Enzymes?
Yes, tigecycline can contribute to elevated liver enzymes. Clinical data and post-marketing reports link it to hepatotoxicity, including increased levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin. These elevations occur in 1-10% of patients, often mildly and reversibly, but severe cases with jaundice or acute liver injury have been documented.[1][2]
How Common Is This in Studies?
In phase 3 trials for complicated skin/skin structure infections and intra-abdominal infections, liver enzyme elevations (ALT/AST >3x upper limit of normal) affected up to 7% of tigecycline patients versus 4% in comparators like vancomycin or imipenem. Most resolved after stopping treatment, but 1-2% experienced bilirubin rises.[3] Real-world data from FDA adverse event reporting shows higher rates, with some cases progressing to liver failure.[1]
What Causes Tigecycline Liver Effects?
Tigecycline, a glycylcycline antibiotic, disrupts bacterial protein synthesis but may induce mitochondrial toxicity in hepatocytes, leading to oxidative stress and enzyme leakage. Risk factors include pre-existing liver disease, prolonged infusions (>14 days), or concurrent hepatotoxins like acetaminophen. It's metabolized via bile and has low renal clearance, concentrating in the liver.[2][4]
What Do Patients Experience?
Symptoms, when present, include fatigue, nausea, abdominal pain, or jaundice alongside lab abnormalities. Most cases are asymptomatic, detected via routine monitoring. Liver function typically normalizes within weeks post-discontinuation, but rechallenge risks recurrence.[1][5]
Monitoring and Risk Management
Guidelines recommend baseline liver tests and weekly monitoring during therapy, especially beyond 14 days. Discontinue if ALT/AST exceed 5x upper limit or bilirubin doubles. Avoid in severe hepatic impairment (Child-Pugh C); dose-adjust for moderate cases.[4][6] No antidote exists; supportive care is standard.
Compared to Other Antibiotics
Tigecycline shows higher hepatotoxicity than beta-lactams (e.g., piperacillin-tazobactam, <2% elevation rate) but similar to some tetracyclines. Versus linezolid or daptomycin, its liver signal is stronger in polymicrobial infections.[3][7]
Sources
[1]: FDA Tigecycline Label
[2]: Hepatology Case Reports on Tigecycline
[3]: Tigecycline Phase 3 Trial Data
[4]: IDSA Guidelines on Glycylcyclines
[5]: FAERS Database Analysis
[6]: LiverTox NIH Profile
[7]: Comparative Antibiotic Hepatotoxicity Review